← All Biolargo, INC filings

Biolargo, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

OQX
BLGO
Biolargo, INC
10-K: BioLargo Reports Steep Losses, Revenue Drop Amid Pooph Litigation
BioLargo, Inc. reported a significant increase in net loss and a 56% revenue decrease for fiscal year 2025, primarily driven by a credit loss from a key customer and ongoing litigation.
OQX
BLGO
Biolargo, INC
10-K: BioLargo Reports Increased Revenue but Continues to Face Going Concern Challenges in 2024 10-K Filing
BioLargo's 2024 10-K filing reveals a 45% revenue increase driven by private-label odor control products, but the company still faces net losses and going concern uncertainties.
OQX
BLGO
Biolargo, INC
10-K: BioLargo and Clyra Medical Enter New Licensing Agreement for Iodine Technology
BioLargo and Clyra Medical have entered into a new licensing agreement, granting BioLargo exclusive rights to Clyra's iodine technology outside of specific medical fields.